Goldman Sachs
QTTB icon

Goldman Sachs’s Q32 Bio QTTB Stock Holding History

Goldman Sachs’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-63,539
Closed -$94.7K – 6705
2025
Q2 		$94.7K Buy
63,539
+19,166
+43% +$32.7K ﹤0.01% 5826
2025
Q1 		$73.2K Buy
44,373
+25,953
+141% +$69.9K ﹤0.01% 5832
2024
Q4 		$63.4K Buy
18,420
+5,986
+48% +$189K ﹤0.01% 5827
2024
Q3 		$555K Buy
12,434
+492
+4% +$18.1K ﹤0.01% 4992
2024
Q2 		$214K Buy
+11,942
New +$286K ﹤0.01% 5238
2024
Q1 		– Sell
-1,381
Closed -$15.1K – 5938
2023
Q4 		$15.1K Sell
1,381
-34
-2% -$497 ﹤0.01% 5461
2023
Q3 		$29.8K Sell
1,415
-54
-4% -$1.1K ﹤0.01% 5322
2023
Q2 		$23.4K Buy
1,469
+32
+2% +$574 ﹤0.01% 5535
2023
Q1 		$26.6K Sell
1,437
-589
-29% -$14.7K ﹤0.01% 5639
2022
Q4 		$46K Sell
2,026
-5,975
-75% -$159K ﹤0.01% 5608
2022
Q3 		$231K Sell
8,001
-182
-2% -$7.42K ﹤0.01% 5418
2022
Q2 		$291K Sell
8,183
-12,475
-60% -$426K ﹤0.01% 5441
2022
Q1 		$1.13M Sell
20,658
-15,943
-44% -$990K ﹤0.01% 4721
2021
Q4 		$2.4M Buy
36,601
+22,206
+154% +$2.16M ﹤0.01% 4103
2021
Q3 		$2.04M Buy
14,395
+457
+3% +$58.2K ﹤0.01% 4181
2021
Q2 		$1.82M Buy
13,938
+11,439
+458% +$1.43M ﹤0.01% 4294
2021
Q1 		$424K Sell
2,499
-945
-27% -$199K ﹤0.01% 5236
2020
Q4 		$700K Sell
3,444
-25,294
-88% -$4.89M ﹤0.01% 4422
2020
Q3 		$5.54M Buy
28,738
+6,755
+31% +$1.51M ﹤0.01% 2814
2020
Q2 		$6.01M Buy
21,983
+19,128
+670% +$5.1M ﹤0.01% 2660
2020
Q1 		$798K Buy
2,855
+21
+0.7% +$6.43K ﹤0.01% 3914
2019
Q4 		$1.05M Buy
2,834
+747
+36% +$214K ﹤0.01% 4095
2019
Q3 		$680K Sell
2,087
-162
-7% -$55.1K ﹤0.01% 4277
2019
Q2 		$792K Sell
2,249
-200
-8% -$78.6K ﹤0.01% 4137
2019
Q1 		$1.22M Buy
2,449
+1,605
+190% +$717K ﹤0.01% 3947
2018
Q4 		$339K Buy
+844
New +$319K ﹤0.01% 4571
2018
Q2 		– Sell
-5,150
Closed -$1.73M – 6082
2018
Q1 		$1.73M Buy
+5,150
New +$1.73M ﹤0.01% 3697

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

Goldman Sachs's QTTB Position: Q3 2025 in Review

Goldman Sachs sold out of Q32 Bio (QTTB) in Q3 2025, closing a stake of 63,539 shares — an estimated $94.7K sold.

Goldman Sachs first reported a position in QTTB in Q1 2018 and held it in 27 quarters. The position peaked at $6.01M in Q2 2020. 53 funds tracked by Wall St. Rank hold QTTB as of Q3 2025.

  • Goldman Sachs reported no remaining Q32 Bio position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 63,539 Q32 Bio shares in Q3 2025, an estimated $94.7K.
  • Goldman Sachs first reported a position in Q32 Bio in Q1 2018 and held it in 27 quarters.
  • Goldman Sachs's Q32 Bio position peaked at $6.01M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.